biote (BTMD) Balance Sheet & Financial Health Metrics
This article provides an overview of biote (BTMD)'s financial health and balance sheet metrics. It highlights key figures such as a negative shareholder equity of $-50.4M and total debt of $107.0M, resulting in a debt-to-equity ratio of -212.4%. The company's EBIT is $35.1M, with an interest coverage ratio of 3.2, and it holds $24.1M in cash and short-term investments.
How this was made
The 30-second read
Why it matters
The negative equity and high debt levels could lead to increased stock volatility and potential downside risk.
Market read
The financial health concerns are specific to BTMD but may influence investor sentiment in the biotech sector.
What to watch
Potential upcoming catalysts such as drug approvals or partnerships could alter the financial outlook positively.
Background
Biote (BTMD) is a biotech company with recent financial disclosures indicating significant balance sheet challenges.
Ticker impact
The article discusses biote (BTMD)'s financial health, highlighting significant balance sheet concerns.
Potential downward pressure on stock price due to financial instability; short-term volatility may increase.
The negative shareholder equity and high debt levels suggest financial weakness, which could lead to a decline in stock price. However, positive EBIT and interest coverage indicate some operational stability, tempering the overall negative outlook.
Market effects
The biotech sector may experience increased scrutiny and cautious trading due to financial distress signals from companies like BTMD.
Limited regional impact; concerns are company-specific rather than sector-wide.
Minimal; the news is specific to BTMD and does not indicate broader global market implications.
Counterpoint
Some investors may view the company's operational profitability (EBIT) as a sign of potential turnaround if debt levels are managed effectively.
Key entities
- CompanyBiote (BTMD)
A biotech firm with recent financial struggles as highlighted in the article.
